Depression and related disorders during the female reproductive cycle

Women's Health

Volumn 5, Issue 5, 2009, Pages 577-587

  Miller, Laura J ^a   Girgis, Christina ^b   Gupta, Renu ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HINES VA HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Depression; Menarche; Perimenopause; Postpartum; Pregnancy; Premenstrual dysphoric disorder; Puberty

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CALCIUM; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESCITALOPRAM; ESTROGEN; FLUOXETINE; FLUVOXAMINE; GONADORELIN AGONIST; MAPROTILINE; NEFAZODONE; NEUROTRANSMITTER; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; VITEX AGNUS CASTUS EXTRACT; ANXIOLYTIC AGENT;

ADAPTATION; AEROBIC EXERCISE; ANXIETY DISORDER; BODY IMAGE; BONE DENSITY; CLIMACTERIUM; CLINICAL TRIAL; COGNITION; COGNITIVE THERAPY; COMORBIDITY; COPING BEHAVIOR; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; EMOTIONAL STABILITY; EXERCISE; FEEDBACK SYSTEM; FEMALE; HUMAN; HYPERTENSION; LUTEAL PHASE; MEDICAL DOCUMENTATION; MENARCHE; MENSTRUAL CYCLE; MULTIPLE CYCLE TREATMENT; ORTHOSTATIC HYPOTENSION; PERINATAL PERIOD; PHOTOTHERAPY; PHYSICAL ACTIVITY; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PSYCHOLOGIC ASSESSMENT; PSYCHOTHERAPY; PUBERTY; PUERPERAL DEPRESSION; REVIEW; RISK ASSESSMENT; SEDATION; SEXUAL ABUSE; SIDE EFFECT; SOCIAL BEHAVIOR; SOCIAL STRESS; PREVALENCE; RISK FACTOR; UNITED STATES;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BODY IMAGE; DEPRESSION; FEMALE; HUMANS; MENARCHE; PREVALENCE; PUBERTY; RISK FACTORS; UNITED STATES;

EID: 69849102985     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.09.44     Document Type: Review

References (112)

1. Manson JE: Prenatal exposure to sex steroid hormones and behavioral/ cognitive outcomes. Metab. 57(Suppl. 2), S16-S21 (2008).
2. Accort EE, Freeman MP, Allen JJ: Women and major depressive disorder: clinical perspectives on causal pathways. J. Womens Health (Larchmt) 17(10), 1583-1590 (2008).
3. McEwen B: Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57, 357-384 (2002).
4. Deecher D, Andree TH, Sloan D, Schechter LE: From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinol. 33(1), 3-17 (2008).
5. Wise DD, Felker A, Stahl SM: Tailoring treatment of depression for women across the reproductive lifecycle: the importance of pregnancy, vasomotor symptoms, and other estrogen-related events in psychopharmacology. CNS Spectr. 13(8), 647-662 (2008).
6. Zahn-Waxler C, Shirtcliff EA, Marceau K: Disorders of childhood and adolescence: gender and psychopathology. Ann. Rev. Clin. Psychol. 4, 275-303 (2008).
7. Angold A, Costello EJ, Worthman CM: Puberty and depression: the roles of age, pubertal status and pubertal timing. Psychol. Med. 28(1), 51-61 (1998).
8. Patton GC, Olsson C, Lyndal B et al.: Predicting female depression across puberty: a two-nation longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry 47(12), 1424-1432 (2008).
9. Ohring R, Graber JA, Brooks-Gunn J: Girls' recurrent and concurrent body dissatisfaction: correlates and consequences over eight years. Int. J. Eat. Disord. 31(4), 404-415 (2002).
10. Fletcher JM: Childhood mistreatment and adolescent and young adult depression. Soc. Sci. Med. 68(5), 799-806 (2009).
11. Hankin BL, Abramson LY: Measuring cognitive vulnerability to depression in adolescence: reliability, validity, and gender differences. J. Clin. Child Adolesc. Psychol. 31(4), 491-504 (2002).
12. Conley CS, Rudolph KD: The emerging sex difference in adolescent depression: interacting contributions of puberty and peer stress. Dev. Psychopathol. 21(2), 593-620 (2009).
13. Kaltiala-Heino R, Kosunen E, Rimpela M: Pubertal timing, sexual behavior and self reported depression in middle adolescence. J. Adolesc. 26(5), 531-545 (2003).
14. Michaud PA, Suris JC, Deppen A: Gender-related psychological and behavioural correlates of pubertal timing in a national sample of Swiss adolescents. Mol. Cell. Endocrinol. 254-255, 172-178 (2006).
15. Ellis BJ, Essex MJ: Family environments, adrenarche, and sexual maturation: a longitudinal test of a life history model. Child Dev. 78(6), 1799-1817 (2007).
16. Gehlert S, Song IH, Chang CH, Hartlage SA: The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol. Med. 39(1), 129-136 (2009).
17. Takeda T, Tasaka K, Sakata M, Murata Y: Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women. Arch. Womens Ment. Health 9(4), 209-212 (2006).
18. Wittchen HU, Becker E, Lieb R, Krause P: Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol. Med. 32(1), 119-132 (2002).
19. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. (4th Edition, Text Revision). American Psychiatric Press, Washington, DC, USA (2000).
20. Endicott J, Amsterdam J, Eriksson E et al.: Is premenstrual dysphoric disorder a distinct clinical entity? Womens Health Gend. Based Med. 8(5), 663-679 (1999).
21. Hylan TR, Sundell K, Judge R: The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J. Womens Health Gend. Based Med. 8(8), 1043-1052 (1999).
22. Potter J, Bouyer J, Trussell J, Moreau C: Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based study. J. Womens Health (Larchmt) 18(1), 31-39 (2009).
23. Halbreich U, Borenstein J, Pearlstein T, Kahn LS: The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/ PMDD). Psychoneuroendocrinol. 28(Suppl. 3), 1-23 (2003).
24. Miller MN, Miller BE: Premenstrual exacerbation of mood disorders. Psychopharmacol. Bull. 35(3), 135-149 (2001).
25. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR: Differentiating behavioral effects of gonadal steroids in women with and those without premenstrual syndrome. N. Eng. J. Med. 338(4), 209-216 (1998).
26. Halbreich U: The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinol. 28(Suppl. 3), 55-99 (2003).
27. Huo L, Straub RE, Schmidt PJ et al.: Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor a gene. Biol. Psychiatry 62(8), 925-933 (2007).
28. Anthony M, Berg MJ: Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: part II. J. Womens Health Gend. Based Med. 11(7), 617-629 (2002)
29. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM: Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356(9236), 1131-1136 (2000).
30. Brown J, O'Brien PM, Marjoribanks J, Wyatt K: Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst. Rev. (2), CD001396 (2009).
31. Eriksson E, Ekman A, Sinclair S et al.: Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 28(2), 195-202 (2008).
32. Miller MN, Miller BE, Chinouth R, Coyle BR, Brown GR: Increased premenstrual dosing of nefazodone relieves premenstrual magnification of depression. Depress. Anxiety 15(1), 48-51 (2002).
33. Cohen LS, Soares CN, Lyster A et al.: Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 24(5), 540-543 (2004).
34. Pearlstein TB, Stone AB, Lund SA et al.: Comparison of fluoxetine, buproprion and placebo in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 17(4), 261-266 (1997).
35. Eriksson E, Hedberg MA, Andersch B, Sundblad C: The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacol. 12(2), 167-176 (1995).
36. Freeman EW, Rickels K, Sondheimer SJ, Polansky M: Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry 56(10), 932-939 (1999).
37. Shah NR, Jones JB, Aperi J et al.: Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet. Gynecol. 111(5), 1175-1182 (2008).
38. Yonkers KA, Holthausen GA, Poschman K, Howell HB: Symptom-onset treatment for women with premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 26(2), 198-202 (2006).
39. Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H: A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J. Clin. Psychiatry 66(6), 769-773 (2005).
40. Miller MN, Newell CL, Miller BE et al.: Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study. J. Womens Health (Larchmt) 17(6), 993-997 (2008).
41. Halbreich U: Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 13(7), 569-572 (2008).
42. Berger CP, Presser B: Alprazolam in the treatment of two subsampes of patients with late luteal phase dyphoric disorder: a double-blind, placebo-controlled crossover study. Obstet. Gynecol. 84(3), 379-385.
43. Freeman EW, Rickels K, Sondheimer SJ, Polansky M: A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274(1), 51-57 (1995).
44. Schmidt PJ, Grover GN, Rubinow DR: Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 50(6), 467-473 (1993).
45. Landen M, Eriksson O, Sundblad C et al.: Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazadone and placebo. Psychopharmacol. (Berl.) 155(3), 292-298 (2001).
46. Rickels K, Freeman E, Sondheimer S: Buspirone in the treatment of premenstrual syndrome. Lancet 1(8641), 777 (1989).
47. Joffe H, Cohen LS, Harlow BL: Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am. J. Obstet. Gynecol. 189(6), 1523-1530 (2003).
48. Yonkers KA, Brown C, Pearlstein TB et al.: Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 106, 492-501 (2005).
49. Joffe H, Petrillo LF, Viguera AC et al.: Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J. Clin. Psychiatry 68(12), 1954-1962 (2007).
50. Wyatt KM, Dimmock PW, Ismail KM, Jones PW, O'Brien PM: The effectiveness of GnRHa with and without 'add back' therapy in treating premenstrual syndrome: a meta ana lysis. BJOG 111(6), 585-593 (2004).
51. Segebladh B, Borgstrom A, Nyberg S, Bixo M, Sundstrom-Peromaa I: Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am. J. Obstet. Gynecol. (2009) (Epub ahead of print).
52. Casper RF, Hearn MT: The effect of hysterectomy and bilateral ooporectromy in women with severe premenstrual syndrome. Am. J. Obstet. Gynecol. 162(1), 105-109 (1990).
53. Studd J: Ovariectomy for menstrual madness and premenstrual syndrome - 19th Century history and lessons for current practice. Gynecol. Endocrinol. 22(8), 411-415 (2006).
54. Schellenberg R: Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo controlled study. BMJ 322(7279), 134-137 (2001).
55. Atmaca M, Kumru S, Tezcan E: Fluoxetine versus vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum. Psychopharmacol. 18(3), 191-195 (2003).
56. Blake F, Salkovskis P, Gath D, Day A, Garrod A: Cognitive therapy for premenstrual syndrome: a controlled trial. J. Psychosom. Res. 45(4), 307-318 (1998).
57. Steege JF, Blumenthal JA: The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J. Psychosom. Res. 37(2), 127-133 (1993).
58. Thys-Jacobs S, Starkey P, Bernstein D, Tian J: Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study group. Am. J. Obstet. Gynecol. 179(2), 444-452 (1998).
59. Pearlstein TB, Steiner M: Premenstrual dysphoric disorder: burden of illiness and treatment update. J. Psychiatry Neurosci. 33(4), 291-301 (2008).
60. Gaynes BN, Gavin N, Meltzer-Brody S et al.: Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid. Rep. Technol. Assess. #119. AHRQ Publication No. 05-E006-2, Agency for Healthcare Research and Quality, Rockville MD (2005).
61. Li D, Liu L, Odouli R: Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Hum. Reprod. 24(1), 146-153 (2009).
62. Davis EP, Glynn LM, Schetter CD, Chicz-Demet A, Sandman CA: Prenatal exposure to maternal depression and cortisol influences infant temperament. J. Am. Acad. Child Adolesc. Psychiatry 46(6), 737-746 (2007).
63. Miller LJ, Rukstalis M: Beyond the 'blues': hypotheses about postpartum reactivity. In: Postpartum Mood Disorders. Miller LJ (Ed.). American Psychiatric Press, Washington, DCUSA 3-19 (1999).
64. Hatton DC, Harrison-Hohner J, Coste S et al.: Symptoms of postpartum depression and breastfeeding. J. Hum. Lact. 21(4), 444-449 (2005).
65. Van Doesum KT, Hosman CM, Riksen-Walraven JM, Hoefnageis C: Correlates of depression mothers' sensitivity toward their infants: the role of maternal, child, and contextual characteristics. J. Am. Acad. Child Adolesc. Psychiatry 46(6), 747-756 (2007).
66. Cogill SR, Caplan HL, Alexandra H, Robson KM, Kumar R: Impact of maternal postnatal depression on cognitive development of young children. Br. Med. J. (Clin. Res. Ed.) 292(6529), 1165-1167 (1986).
67. Whitaker RC, Orzol SM, Kahn RS: Maternal mental health, substance use, and domestic violence in the year after delivery and subsequent behavior problems in children at age 3 years. Arch. Gen. Psychiatry 63(6), 551-560 (2006).
68. Steiner M, Tam WYK: Postpartum depression in relation to other psychiatric disorders. In: Postpartum Mood Disorders. Miller LJ (Ed.). American Psychiatric Press, Washington, DC, USA 47-63 (1999).
69. Attia E, Downey J, Oberman M: Postpartum psychoses. In: Postpartum Mood Disorders. Miller LJ (Ed.). American Psychiatric Press, Washington, DC, USA 99-117 (1999).
70. Heron J, Robertson Blackmore E, McGuinness M, Craddock N, Jones I: No 'latent period' in the onset of bipolar affective puerperal psychosis. Arch. Womens Ment. Health 10(2), 79-81 (2007).
71. Dean C, Kendell RE: The symptomatology of puerperal illnesses. Br. J. Psychiatry 139, 128-133 (1981).
72. Oosthuizen P, Russouw H, Roberts M: Is puerperal psychosis bipolar mood disorder? A phenomenological comparison. Compr. Psychiatry 36(1), 77-81 (1995).
73. Wisner KL, Peindl K, Hanusa BH: Symptomatology of affective and psychotic illnesses related to childbearing. J. Affect. Disord. 30(2), 77-87 (1994).
74. Altemus M, Fong J, Yang R et al.: Changes in cerebrospinal fluid neurochemistry during pregnancy. Biol. Psychiatry 56(6), 386-392 (2004).
75. Corwin EJ, Pajer K: The psychoneuroimmunology of postpartum depression. J. Womens Health (Larchmt) 17(9), 1529-1534 (2008).
76. Yim IS, Glynn LM, Dunkel Schetter C et al.: Risks of postpartum depressive symptoms with elevated corticotrophin-releasing hormone in human pregnancy. Arch. Gen. Psychiatry 66(2), 162-169 (2009).
77. Tammentie T, Paavilainen E, Astedt-Kurki P, Tarkka MT: Family dynamics of postnatally depressed mothers - discrepancy between expectations and reality. J. Clin. Nurs. 13(1), 65-74 (2004).
78. Cohen LS, Altshuler LL, Harlow BL et al.: Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295(5), 499-507 (2006).
79. Miller LJ, Bishop JR, Fischer JH, Geller SE, Macmillan C: Balancing risks: dosing strategies for antidepressants near the end of pregnancy. J. Clin. Psychiatry 69(2), 323-324 (2008).
80. Spinelli MG, Endicott J: Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am. J. Psychiatry 160(3), 555-562 (2003).
81. Forman DR, O'Hara MW, Stuart S et al.: Effective treatment for postpartum depression is not sufficient to improve the developing mother-child relationship. Dev. Psychopathol. 19(2), 585-602 (2007).
82. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL: Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch. Gen. Psychiatry 63(4), 385-390 (2006).
83. Freeman EW, Sammel MD, Lin H, Nelson DB: Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch. Gen. Psychiatry 63(4), 375-382 (2006).
84. Richards M, Rubinow DR, Daly RC, Schmidt PJ: Premenstrual symptoms and perimenopausal depression. Am. J. Psychiatry 163(1), 133-137 (2006).
85. Soares CN, Zitek B: Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J. Psychiatry Neurosci. 33(4), 331-343 (2008).
86. Alexander JL, Dennerstein L, Woods NF et al.: Role of stressful life events and menopausal stage in wellbeing and health. Expert Rev. Neurother. 7(Suppl. 11), S93-S113 (2007).
87. Schmidt PJ, Murphy JH, Haq N, Rubinow DR, Danaceau MA: Stressful life events, personal losses, and perimenopause-related depression. Arch. Womens Ment. Health 7(1), 19-26 (2004).
88. Kaufert PA: A health and social profile of the menopausal woman. Exp. Gerontol. 29(3-4), 343-350 (1994).
89. Joffe H, Hall JE, Soares CN et al.: Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 9(6), 392-398 (2002).
90. Clayton A, Guico-Pabia C: Recognition of depression among women presenting with menopausal symptoms. Menopause 15(4 Pt 1), 758-767 (2008).
91. Bromberger JT, Kravitz HM, Matthews K et al.: Predictors of first lifetime episodes of major depression in midlife women. Psychol. Med. 39(1), 55-64 (2009).
92. Standing TS, Glazer G: Attitudes of low-income clinic patients toward menopause. Health Care Women Int. 13(3), 271-280 (1992).
93. Van der Kooy K, van Hout H, Marwijk H et al.: Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int. J. Geriatr. Psychiatry 22(7), 613-616 (2007).
94. Gonzalez JS, Peyrot M, McCarl LA et al.: Depression and diabetes treatment non-adherence: a meta-analysis. Diabetes Care 31(12), 2398-2403 (2008).
95. Williams LJ, Pasco JA, Jacka FN et al.: Depression and bone metabolism: a review. Psychother. Psychosom. 78(1), 16-25 (2009).
96. Gyllstrom ME, Schreiner PJ, Harlow BL: Perimenopause and depression: strength of association, causal mechanisms and treatment recommendations. Best Pract. Res. Clin. Obstet. Gynecol. 21(2), 275-292 (2007).
97. Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA 282(18), 1737-1744 (1999).
98. Jenkins MR, Sikon AL: Update on nonhormonal approaches to menopausal management. Cleve. Clin. J. Med. 75(Suppl. 4), S17-S24 (2008).
99. Stahl SM, Grady MM, Moret C, Briley M: SNRIs: their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants. CNS Spectr. 10(9), 732-747 (2005).
100. Vestergaard P: Fracture risk of antidepressants. Expert Rev. Neurother. 9(1), 137-141 (2009).
101. Schmidt PJ, Nieman L, Danaceau MA et al.: Estrogen replacement in perimenopause-related depression: a preliminary report. Am. J. Obstet. Gynecol. 183(2), 414-420 (2000).
102. Soares CN, Almeida OP, Joffe H, Cohen LS: Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch. Gen. Psychiatry 58(6), 529-534 (2001).
103. Morrison MF, Kallan MJ, Ten Have T et al.: Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol. Psychiatry 55(4), 406-412 (2004).
104. Westlund Tam L, Parry BL: Does estrogen enhance the antidepressant effects of fluoxetine? J. Affect. Disord. 77(1), 87-92 (2003).
105. Morgan ML, Cook IA, Rapkin AJ, Leuchter AF: Neurophysiologic changes during estrogen augmentation in perimenopausal depression. Maturitas 56(1), 54-60 (2007).
106. Swartz HA, Frank E, Shear MK, Thase ME, Fleming MA, Scott J: A pilot study of brief interpersonal psychotherapy for depression among women. Psychiatr. Serv. 55(4), 448-450 (2004).
107. Feldman G: Cognitive and behavioral therapies for depression: overview, new directions, and practical recommendations for dissemination. Psychiatr. Clin. N. Am. 30(1), 39-50 (2007).
108. Pines A, Berry EM: Exercise in the menopause - an update. Climacteric 10(Suppl. 2), 42-46 (2007).
109. Conroy MB, Simkin-Silverman LR, Pettee KK et al.: Lapses and psychological factors related to physical activity in early postmenopause. Med. Sci. Sports Exerc. 39(10), 1858-1866 (2007).
110. Speck BJ, Harrell JS: Maintaining regular physical activity in women: evidence to date. J. Cardiovasc. Nurs. 18(4), 282-291 (2003).
111. Segar ML, Eccles JS, Richardson CR: Type of physical activity goal influences participation in healthy midlife women. Womens Health Issues 18(4), 281-291 (2008).
112. Segar M, Jayaraine T, Hanlon J, Richardson CR: Fitting fitness into women's lives: effects of a gender-tailored physical activity intervention. Womens Health Issues 12(6), 338-347 (2002).